BioLineRx (NASDAQ:BLRX) Stock Passes Above Two Hundred Day Moving Average – What’s Next?

Posted by ABMN Staff on May 27th, 2026

BioLineRx Ltd. (NASDAQ:BLRX – Get Free Report)’s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.88 and traded as high as $3.37. BioLineRx shares last traded at $3.16, with a volume of 60,317 shares traded.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioLineRx in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Read Our Latest Stock Report on BioLineRx

BioLineRx Trading Up 3.3%

The stock has a market cap of $13.75 million, a price-to-earnings ratio of -18.59 and a beta of 1.42. The company has a quick ratio of 1.78, a current ratio of 1.95 and a debt-to-equity ratio of 0.19. The business has a 50-day moving average of $2.60 and a 200-day moving average of $2.88.

BioLineRx (NASDAQ:BLRX – Get Free Report) last released its quarterly earnings data on Tuesday, March 24th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.16. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.49 million. BioLineRx had a negative return on equity of 5.61% and a negative net margin of 99.58%.

About BioLineRx

(Get Free Report)

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.